What Is Terlipressin Approved For? Label Indications, Per the Research

Where Terlipressin Is Used and Who Administers It

Terlipressin is a prescription vasopressin analogue that is administered by clinicians in a monitored clinical setting, typically a hospital ward, an infusion area or a critical-care unit, rather than in any self-directed context. A formulary review published in Hospital Pharmacy described terlipressin as an intravenous synthetic vasopressin analogue used under specialist supervision in patients with advanced liver disease (PMID 38560548). Because candidate patients are usually hospitalised with decompensated cirrhosis and failing kidneys, every decision about whether the drug fits a given case sits with the treating hepatology, nephrology and critical-care team.

This page summarises what the published regulatory and trial literature states about the labelled indication. It does not describe administration, preparation or monitoring, and it is not a substitute for the prescribing information or for a conversation with a prescriber.

The Labelled Indication in the United States

The United States approval covers hepatorenal syndrome with rapid reduction in kidney function, the condition described in the clinical literature as hepatorenal syndrome type 1 or, in more recent nomenclature, hepatorenal syndrome acute kidney injury (HRS-AKI). A review of peptide and oligonucleotide therapeutics approved by the FDA recorded terlipressin among the 2022 approvals in that class (PMID 36986436). The Hospital Pharmacy formulary review of terlipressin set out the same indication, describing the agent as approved for adults with hepatorenal syndrome accompanied by rapid deterioration in renal function (PMID 38560548).

That phrasing matters. The label is narrow: it addresses a specific, rapidly progressive form of kidney failure arising in the setting of advanced cirrhosis and ascites, not kidney injury in cirrhosis generally, and not every patient who carries a hepatorenal syndrome diagnosis. A 2023 review in Clinical Gastroenterology and Hepatology on pharmacologic therapies for HRS-AKI placed terlipressin within the broader group of vasoconstrictor strategies used alongside albumin for this syndrome (PMID 37625864).

What Hepatorenal Syndrome Is, in Brief

Hepatorenal syndrome is described in the literature as a functional form of kidney failure that develops in advanced cirrhosis, driven by splanchnic arterial vasodilation, reduced effective arterial blood volume and renal vasoconstriction rather than by structural kidney damage. A 2023 review in Clinical and Molecular Hepatology summarised these mechanisms and the evolving diagnostic criteria for the syndrome (PMID 37050843). A 2023 review in Medical Clinics of North America covered pathophysiology, diagnosis and treatment of the same syndrome, including the role of vasoconstrictor therapy combined with albumin (PMID 37258014). A 2022 review in Clinics in Liver Disease addressed definitions, diagnosis and management and underscored that accurate classification determines which patients are considered for drug therapy at all (PMID 35487604).

The Pivotal Trial Behind the Indication

The approval rested on the CONFIRM trial, published in The New England Journal of Medicine in 2021, which randomly assigned 300 adults with hepatorenal syndrome type 1 in a 2:1 ratio to terlipressin or placebo, each given with albumin (PMID 33657294). In that trial terlipressin was administered intravenously at 1 mg every 6 hours alongside albumin, according to the published report (PMID 33657294). This is a description of what researchers did in a controlled hospital trial and is not guidance for any individual.

The primary endpoint was verified reversal of hepatorenal syndrome, and the study reported that this occurred in 32 percent of patients assigned to terlipressin compared with 17 percent of those assigned to placebo (PMID 33657294). The trial investigators also reported that the difference in overall survival between the groups was not statistically significant (PMID 33657294). Subsequent reviews of HRS-AKI pharmacotherapy discussed these results in the context of comparator vasoconstrictors and of albumin as background therapy (PMID 37625864).

How the Labelled Population Is Framed in Reviews

A 2024 review in Advances in Kidney Disease and Health focused specifically on the diagnosis and treatment of hepatorenal syndrome type 1 and described terlipressin within the treatment pathway for that population (PMID 38649214). A companion contemporary review in the same journal on renal replacement therapy in cirrhosis described dialysis decisions in patients with liver failure and kidney injury, a separate consideration from pharmacologic vasoconstriction (PMID 38649217). Reviews of this kind consistently frame terlipressin as one element of hospital-level management rather than a standalone intervention, and the treating specialist team decides whether it is appropriate.

Approved Versus Investigational: A Clear Separation

The distinction below reflects what the cited literature states. Anything described as investigational has not been established as an approved indication in the United States, and nothing on this page should be read as encouraging use outside a label.

Variceal Bleeding in the Published Reviews

Gastroesophageal variceal bleeding is a distinct complication of portal hypertension, and vasoactive drug therapy is a long-standing part of its management in the published literature. A 2024 review in the World Journal of Hepatology on contemporary prevention and management of gastroesophageal variceal bleeding in cirrhosis described the place of vasoactive agents alongside endoscopic therapy and antibiotics (PMID 38495286). Regulatory status for this use differs between jurisdictions, and the United States labelled indication for terlipressin described in the formulary review was hepatorenal syndrome with rapid reduction in kidney function (PMID 38560548). Readers comparing international practice guidance with a national label should raise that difference with a prescribing clinician rather than assume equivalence.

Investigational Formulation Work

Research into modified terlipressin molecules remains at a preclinical stage. A 2024 report in ACS Pharmacology and Translational Science described a long-circulating 1,18-octadecanedioic acid terlipressin conjugate designed to extend vasoactive exposure, work carried out in a laboratory and animal setting (PMID 38751631). Investigational conjugates of this kind are not approved products and have no labelled indication.

Adverse Events: What Studies Report

Safety findings shaped how the labelled population is defined, so they are part of any accurate account of the indication. In CONFIRM, researchers reported that abdominal pain, nausea, diarrhoea and respiratory failure occurred more frequently among patients assigned to terlipressin than among those assigned to placebo (PMID 33657294). The trial also reported that death within 90 days attributed to respiratory disorders occurred in 11 percent of the terlipressin group compared with 2 percent of the placebo group (PMID 33657294).

The Hospital Pharmacy formulary review discussed safety monitoring considerations for terlipressin in the institutional setting, including the need for oxygenation assessment and patient selection (PMID 38560548). Reviews of HRS-AKI pharmacotherapy similarly weighed ischaemic and respiratory risks against the likelihood of renal response when discussing which patients are considered candidates (PMID 37625864). A 2024 review of hepatorenal syndrome type 1 placed the same risk considerations within the broader treatment pathway, including transplant evaluation (PMID 38649214).

Why the Label Is Narrower Than the Diagnosis

Hepatorenal syndrome terminology has shifted over the past decade, and reviews note that patients once grouped under a single label are now separated by acuity and by the presence or absence of structural kidney injury. The 2023 Clinical and Molecular Hepatology review described these changing definitions and their effect on which patients enter trials (PMID 37050843). The 2022 Clinics in Liver Disease review emphasised that diagnosis requires exclusion of other causes of acute kidney injury and a trial of volume expansion before a hepatorenal label is applied (PMID 35487604). Because of this, the clinical question is rarely simply whether a drug is approved, but whether a specific patient matches the population studied, and that assessment belongs to the treating team.

Questions a Patient or Caregiver Might Raise With the Specialist Team

• Which form of kidney injury has been diagnosed, and how does it map to the hepatorenal categories described in the review literature (PMID 37258014)?
• What role does albumin play alongside any vasoconstrictor in the current plan, as discussed in HRS-AKI pharmacotherapy reviews (PMID 37625864)?
• How are breathing and oxygen levels being monitored, given the respiratory findings reported in the pivotal trial (PMID 33657294)?
• How do dialysis and transplant evaluation fit into the same decision, as described in contemporary reviews of renal replacement therapy in cirrhosis (PMID 38649217)?

Key Points

1. The United States labelled indication is hepatorenal syndrome with rapid reduction in kidney function in adults, recorded among 2022 peptide approvals (PMID 36986436).
2. The pivotal CONFIRM trial reported verified hepatorenal syndrome reversal in 32 percent of terlipressin patients versus 17 percent on placebo, with no statistically significant survival difference (PMID 33657294).
3. Respiratory failure and respiratory-related deaths were reported more often with terlipressin than placebo in that trial (PMID 33657294).
4. Variceal bleeding management is discussed separately in the review literature and is not the United States hepatorenal indication (PMID 38495286, PMID 38560548).
5. Long-acting conjugate versions remain investigational preclinical work (PMID 38751631).

This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing specialist team about any question involving terlipressin, hepatorenal syndrome or liver disease care. Talk to your prescriber before drawing any conclusion from the literature summarised here.

References

• Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome (The New England Journal of Medicine, 2021)
• Formulary Drug Reviews: Terlipressin (Hospital Pharmacy, 2023)
• 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest (Pharmaceuticals, 2023)
• Hepatorenal syndrome: Current concepts and future perspectives (Clinical and Molecular Hepatology, 2023)
• Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment (The Medical Clinics of North America, 2023)
• Hepatorenal Syndrome: Definitions, Diagnosis, and Management (Clinics in Liver Disease, 2022)
• Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury (Clinical Gastroenterology and Hepatology, 2023)
• Hepatorenal Syndrome Type 1: Diagnosis and Treatment (Advances in Kidney Disease and Health, 2024)
• Renal Replacement Therapy in Cirrhosis: A Contemporary Review (Advances in Kidney Disease and Health, 2024)
• Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients (World Journal of Hepatology, 2024)
• Long-Circulating Vasoactive 1,18-Octadecanedioic Acid-Terlipressin Conjugate (ACS Pharmacology and Translational Science, 2024)